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UBy any standard, cardiac surgery has been a spectacularly
dynamic field of medicine. The introduction of major surgi-
cal innovations and ongoing incremental change in such
areas as coronary artery bypass grafting (CABG), cardiac
valve replacement and repair, myocardial protection, me-
chanical circulatory support, aortic reconstruction, and the
treatment of arrhythmias have extended survival and im-
proved quality of life for many patients with cardiac dis-
ease. A rapid pace of innovation requires a rigorous
infrastructure for clinical evaluation that provides timely
assessments of the value of new treatments.
This need is underscored by the significant prevalence of
and cost associated with cardiovascular diseases. In fact,
medical care for cardiovascular diseases accounted for 6
of the 20 most expensive conditions billed to Medicare in
2006, totaling $103 billion. Cardiac surgery is an important
part of the therapeutic armamentarium, and its application
to targeted populations has evolved considerably over the
past several years. Surgical investigators have championed
less invasive methods of caring for increasingly older and
sicker patients with a variety of diseases and high expecta-
tions for robust outcomes. Evaluating the benefits of surgi-
cal intervention in the modern era requires careful
consideration of risk and cost/benefit tradeoffs.
Many surgical procedures have undergone extensive clin-
ical trials. CABG surgery is arguably one of the most widely
studied surgical procedures ever, with several large-scale
randomized trials starting in the 1970s and continuing,
most recently, with the Surgical Treatments of Ischemic
Heart Failure (STICH) Trial, which randomized approxi-
mately 2000 patients with ischemic cardiomyopathy. Yet
a National Heart, Lung, and Blood Institute working group
in 2004 concluded that there were substantial impediments
to clinical trials of cardiac surgical procedures and that the
field lacked the necessary organizational infrastructure to
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oration with the National Institute for Neurological Disor-
ders and Stroke and the Canadian Institutes for Health
Research, created the Cardiothoracic Surgery Trials Net-
work in the fall of 2007 to fill this lacuna. The mission of
the network is to design, conduct, and analyze multiple,
collaborative clinical trials that evaluate surgical interven-
tions and related management approaches for the treatment
of cardiovascular disease in adult patients. The network has
developed a portfolio of trials that evaluate clinically mean-
ingful questions and address important public health issues.COMPARATIVE EFFECTIVENESS TRIALS
In recent years, there has been increasing recognition that
the evidence base underlying much of clinical practice is in-
adequate, a deficiency that is also true for cardiac surgery. A
recent review of American College of Cardiology/Ameri-
can Heart Association guidelines, for instance, found that
only 11% of recommendations were based on high-
quality evidence.2 This limitation implies that a substantial
number of commonly used procedures lack an appropriate
evidence base for effective clinical decision making. This
realization has been a driving force for the selection of ran-
domized trials by the network.
One area of focus is ischemic mitral regurgitation (MR),
which is estimated to affect 2.8 million Americans. In this
issue of the Journal, investigators discuss the design of
the severe ischemic MR trial,3 which evaluates the safety
and efficacy of mitral valve repair versus mitral valve re-
placement in patients with severe MR identified echocar-
diographically by using an integrative method, and the
moderate ischemic MR trial,4 which evaluates the safety
and efficacy of CABG plus mitral valve repair versus
CABG alone. Another critical area is the treatment of atrial
fibrillation (AF), including surgical ablation, which the In-
stitute of Medicine recently ranked within the first quartile
of the 100 priorities for comparative effectiveness research.
The network’s AF trial5 also described in this issue com-
pares left atrial appendage closure plus surgical ablation
with left atrial appendage closure alone for (long-standing)
persistent AF in patients undergoing mitral valve surgery.
Nested within this trial is a comparison of 2 different lesion
sets in the ablation group (pulmonary vein isolation alone vs
a biatrial lesion set), which will provide preliminary data to
guide development of a follow-up trial. In addition, network
investigators received challenge grant funding to develop
a randomized trial comparing hybrid revascularization
procedures with multivessel percutaneous coronaryrdiovascular Surgery c Volume 142, Number 2 265
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Uintervention with drug-eluting stents in patients with multi-
vessel coronary artery disease involving the left anterior de-
scending artery. This funding supports an observational
study to collect preliminary data on patients’ eligibility
and outcomes after percutaneous coronary intervention
and hybrid procedures using left internal thoracic artery–
left anterior descending artery bypass, as well as to support
the development of a finalized protocol for a pivotal trial.
QUALITY IMPROVEMENT STUDIES
Hospital-acquired infections represent the major noncar-
diac complication after heart surgery and are associated
with substantial morbidity, higher mortality, prolonged hos-
pitalizations, and increased rates of readmission. Although
prior studies have examined the relationship between pa-
tients’ characteristics (eg, comorbid conditions) and
hospital-acquired infections after cardiac surgery, the liter-
ature has not sufficiently examined the relationship between
treatment/management practices (eg, line management and
ventilator management) and postoperative infection risk.
Knowledge about this relationship is critical to developing
interventions to avert infections. The network recently en-
rolled more than 5200 patients in a prospective cohort study
that assesses major infections (eg, deep surgical site infec-
tion, endocarditis, mediastinitis, and pneumonia) and minor
infections (eg, superficial surgical site infections and symp-
tomatic urinary tract infections) after cardiac surgery. This
study analyzes management practices that might put pa-
tients at high risk for infections and should provide insights
to help guide the development of more effective strategies
for reducing these debilitating and costly complications.
TRIALS IN THE PIPELINE
In addition to comparative effectiveness trials and quality
improvement studies, the network is developing smaller tri-
als of novel interventions, notably stem cell therapy. The
management of advanced heart failure has increasingly be-
come the domain of both cardiologists and surgeons, with
transplantation and left ventricular assist device (LVAD)
therapy. Both therapies provide significant survival benefits,
but transplantation is limited by the supply of donor organs,
and LVAD therapy is still plagued by adverse events, al-
though these are decreasing with newer-generation devices
and improvements in patient management. These risks
could be minimized further if the duration of support could
be limited by inducing myocardial recovery, which could
lead to explantation, in which case LVAD use would be-
come a short-term therapeutic rescue. One promising ave-
nue to improve performance is the intramyocardial
injection of mesenchymal precursor cells, which might en-
graft and provide a renewable source of functional cardio-
myocytes and a network of new blood vessels and266 The Journal of Thoracic and Cardiovascular Surgpromote the release of factors capable of paracrine signal-
ing. The network, in collaboration with the Cardiovascular
Cell Therapy Research Network, is completing the protocol
for a phase II trial that will evaluate the safety and explore
the efficacy of direct myocardial injection of 2 different
doses of mesenchymal precursor cells in LVAD recipients
awaiting cardiac transplantation.
Another promising cell type is cardiac stem cells (CSCs).
The network is currently developing a proof-of-concept
study to explore the safety, efficacy, and feasibility of intra-
coronary injections of autologous CSCs after cardiac trans-
plantation. This trial will provide important exploratory
information regarding the effects of CSCs on myocardial
function after transplantation (with the ultimate objective
of modulating tolerance and reducing the incidence of
allograft rejection) and the ability of CSCs to engraft and
differentiate within the scaffold of the transplanted heart.
Finally, network investigators are exploring the develop-
ment of a randomized trial to evaluate the effectiveness and
safety of endovascular stent graft treatment of patients with
acute, uncomplicated type B, aortic dissection at high risk
for complications.SOME CONCLUDING OBSERVATIONS
These trials and observational studies constitute the first
phase of the network’s activities. Much has been learned by
the surgical investigators, data-coordinating center, and
Institute leadership. Notable insights include the impor-
tance of establishing a dedicated culture of research at
each investigative site, cultivating a collaborative relation-
ship with the cardiology community, and recognizing the
need to define equipoise in randomized trials, especially
when choosing between (or among) available surgical and
medical options. The value of these attributes cannot be
overestimated. It is anticipated that the research of the net-
work will offer important insights and lay the foundation for
larger randomized trials to further strengthen the evidence
base that should guide clinical decision making.References
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